Evidence map›Paper›PMID 41073632›Full record

Observational studyScientific reports2025

Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study.

Xiaoyun Cheng, Lingzhi Long, Yuzhang Li, Xia Gan, Pan Yu, Xiangyu Zhang, Guoliang Jiang, Tingting Yao, Mao Jiang, Wei Xie and 1 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoyun ChengDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Lingzhi LongDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Yuzhang LiDepartment of Cardiology, Xiangya Hospital of Central South University, Changsha, 410008, China.
Xia GanRadiation Oncology Center, Hunan Cancer Hospital, Changsha, 410013, China.
Pan YuDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Xiangyu ZhangDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Guoliang JiangDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Tingting YaoDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Mao JiangDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China.
Wei XieDepartment of Cardiology, Xiangya Hospital of Central South University, Changsha, 410008, China. 18987000331cxy@sina.cn.
Jie MengDepartment of Pulmonary and Critical Care Medicine, The Third XiangyaHospital of Central South University, Changsha, 410013, China. mengjie@csu.edu.cn.

Funding

the National Natural Science Foundation of China 82270079the National Natural Science Foundation of China 82300096
6 · The paper itself

Abstract

Immune checkpoint inhibitor (ICI)-related myocarditis is a rare but fatal immune-related adverse event in lung cancer patients, with limited multivariate prognostic analysis. This study aimed to identify risk factors for severity, major adverse cardiac events (MACE) and survival time, and develop a survival prediction model. Data from 70 lung cancer patients with ICI-related myocarditis (training set) and 40 patients (validation set) were analyzed, with ≥ 1.5 years of follow-up. Cox regression was employed to determine factors associated with survival time, and Logistic regression models identified risk factors for severe myocarditis and MACE. Several factors were independently associated with all-cause death: protective factors included combined radiotherapy (HR 0.12, 95%CI: 0.01-0.98, p = 0.047) and longer ICI treatment duration (≥ 132 days, HR 0.93, 95%CI: 0.91-0.98, p = 0.013); risk factors included low-dose glucocorticoid use in patients with severe myocarditis (HR 3.92, 95%CI: 1.16-13.2, p = 0.028). A nomogram model constructed based on these three variables yielded area under the time-ROC curves of 0.832, 0.835, and 0.924 for 0.5-, 1-, and 1.5-year survival in the training set, and 0.821, 0.806, and 0.789 in the validation set, respectively. It also demonstrated good discriminative ability and clinical utility for predicting survival in lung cancer patients with ICI-related myocarditis, as this study established a validated nomogram model that may aid survival prediction in this population. Additionally, we analyzed the risk factors for severe ICI related myocarditis and 90-day MACE. We found that the use of angiogenesis inhibitors was an independent risk factor for severe myocarditis (OR 18.72, 95% CI: 2.52-428.27, p = 0.02); a history of coronary artery disease (OR 10.54, 95% CI: 1.62-210.10, p = 0.037) was an independent risk factor for 90-day MACE; and left ventricular ejection fraction (OR 0.94, 95% CI: 0.88-0.99, p = 0.026) was an independent protective factor against 90-day MACE.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsMyocarditisAgedFemaleHumansMaleMiddle AgedNomogramsPrognosisRisk FactorsImmune Checkpoint InhibitorsImmune checkpoint inhibitor-related myocarditisLung cancerMACESurvival analysis

Identifiers

PMID41073632
PMCPMC12514198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.